THE SOCS5 and SOCS7 transcript levels didn’t show significant differences (p = 0.3) between MS patients (0.91 ± 0.14 and 0.82 ± 0.13 respectively) and the control group (1.006 ± 0.16 and 1.008 ± 0.18) (Figure 1A). This evidence concerns the gene SOCS7 and myeloid sarcoma.